Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

  1. Sangro, B.
  2. Galle, P.R.
  3. Kelley, R.K.
  4. Charoentum, C.
  5. De Toni, E.N.
  6. Ostapenko, Y.
  7. Heo, J.
  8. Cheng, A.-L.
  9. Wilson Woods, A.
  10. Gupta, C.
  11. Abraham, J.
  12. McCoy, C.L.
  13. Patel, N.
  14. Negro, A.
  15. Vogel, A.
  16. Abou-Alfa, G.K.
Revista:
Journal of Clinical Oncology

ISSN: 1527-7755 0732-183X

Any de publicació: 2024

Volum: 42

Número: 23

Pàgines: 2790-2799

Tipus: Article

DOI: 10.1200/JCO.23.01462 GOOGLE SCHOLAR lock_openAccés obert editor